Τρίτη 16 Οκτωβρίου 2018

Evaluating the Impact of Broadly Neutralizing Antibodies VRC01LS and 10-1074 on Maintenance of HIV Suppression in a Cohort of Early-Treated Children in Botswana (Dual bNAb Treatment in Children)

Condition:   HIV Infection Interventions:   Drug: ART;   Biological: VRC01LS;   Biological: 10-1074 Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting (Source: ClinicalTrials.gov)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.



from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2P2qClw

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.